Intellia Awaits Phase 3 Data on CRISPR Gene Editing Therapy for Hereditary Angioedema

Event summary

  • Intellia Therapeutics will report topline data from a Phase 3 clinical trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) on April 27, 2026.
  • The trial represents the first Phase 3 readout for an in vivo CRISPR gene editing candidate.
  • A webcast to discuss the data will be held at 8:00 a.m. ET on April 27, 2026.
  • Lonvoguran ziclumeran (lonvo-z) is being developed to treat HAE, a genetic disorder causing painful swelling.

The big picture

Intellia's trial represents a pivotal moment for the nascent field of in vivo CRISPR gene editing. The success or failure of lonvoguran ziclumeran will significantly impact investor sentiment and the broader trajectory of gene editing therapeutics, potentially opening doors for other companies pursuing similar approaches. While the HAE market is relatively small, the trial's outcome carries implications far beyond this indication, signaling the viability of CRISPR for treating other genetic diseases.

What we're watching

Clinical Efficacy
The trial's success hinges on demonstrating statistically significant and clinically meaningful efficacy compared to existing HAE treatments, which will heavily influence future development and commercial prospects.
Regulatory Pathway
The FDA and other regulatory bodies will scrutinize the data for safety and efficacy, and the trial's design and results will shape the potential approval pathway for in vivo CRISPR therapies.
Market Adoption
Even with approval, the high cost of gene editing therapies will likely limit initial adoption, and Intellia will need to demonstrate a clear value proposition to payers and patients.

Related topics

Biotechnology